Biopeople

Award winners

Award winners

19.02.2013 - Three researchers – one from the UK and two from Germany – have been awarded the Louis-Jeantet prize for Medicine.

Michael Stratton, Chief of the Wellcome Trust Sanger Institute in Hinxton, UK, and the two German biochemists Peter Hegemann, Berlin, and Georg Nagel, Würzburg (photo), will receive a prize money of CHF700,000. Stratton got the prize, of which CHF75,000 is for personal use, for his work aimed at understanding the genetic causes of human cancer. He discovered the roles of the BRCA2 and BRAF genes in breast and skin cancers. Hegemann and Nagel, who share the prize, pioneered the field of optogenetics, a technique to control gene expression by switching light on and off. Namely, they discovered ion channels that can be activated by light.

06.05.2013 Swedish Vitrolife AB proposed Carsten Browall as new Chairman of the Board.

He will follow Patrik Tigerschiöld, who declined reelection after 13 years on the Board and 11 years as its Chairman. Browall has been a member of the Vitrolife Board since 2012, and has many years of experience as an executive within the med-tech and healthcare sector. During his career he has worked at Unfors RaySafe, Mölnlycke Health Care, Nobel Biocare and Capio.

03.05.2013 Paris-based developer of non-viral gene therapy for ocular diseases Eyevensys SA has named Dr. Ivan Cohen-Tanugi as its new CEO.

Cohen-Tanugi brings the company more than 20 years of experience in the international pharmaceutical industry. He will prepare Eyevensys to launch clinical trials for the company's non-viral gene therapy products in two ophthalmic indications - uveitis and age-related macular degeneration - within the next 18 months. Cohen-Tanugi has considerable experience in biologics and in the pharmaceutical industry at an international level, notably in the fields of sales and marketing, global product launches, R&D team leadership and financing. The physician and MBA joins Eyevensys from Teva Pharmaceuticals, where he was Vice President and General Manager of the US Biologics and Specialty unit. Cohen-Tanugi began his career at Sanofi, then worked for many years with Roche Pharma in Basel. Prior to his activities at Teva, he was employed with Amgen International.

23.04.2013 Oern Stuge has taken over from Henry Hyde Thomson as Chairman at Phagenesis plc (Manchester) to support the rollout of the company’s dysphagia therapy Phagenyx.

Stuge previously served as Senior Executive at Medtronic and Abbott Laboratories. He began his career as a practicing physician. He has an MD from the University of Oslo, as well as an MBA from IMD in Lausanne.

22.04.2013 Molecular diagnostics specialist Curetis AG (Holz-gerlingen) is expanding into new markets with ELI-Tech BNL as a new partner in Belgium and Luxembourg, and it has also acquired a new Head of Business Development.

Helmut Hilbert, a former Associate Director of Corporate Business Development at Qiagen, will strengthen the company's global commercial operations. Hilbert has more than ten years of business and corporate development experience, and has a strong track record in licensing, mergers and acquisitions, technology transfer and innovation management.

19.04.2013 French diabetes specialist Poxel SA (Lyon) has beefed up its business strategy expertise by appointing Khoso Baluch to its Board of Directors.

Baluch is currently Senior VP & President European Region at Belgian UCB SA. Prior to his career there, he worked with Eli Lilly for 24 years, holding international positions in General Management, Business Development, Market Access and Product Leadership. He served as a Board Member of the Juvenile Diabetes Research Foundation, Indiana Chapter, and was Chair of the nomination committee. He also served at the American Diabetes Association National Industry Advisory Board and is also a member of the World Federation of Advertisers (WFA) Executive Committee. Poxel was spun-out from Merck Serono in 2009.

14.05.2013 Dr. Michel Pairet, Boehringer Ingelheim's head of non-clinical R&D, has joined Eyevensys' board of directors.

The appointment followed an investment from the Boehringer Ingelheim Venture Fund in the French developer of electrotransfer-based non-viral gene therapy. Prior to his responsibilites for preclinical research, Pairet was in charge of Boehringer's worldwide research and its corporate investment fund.

13.05.2013 Norwegian targeted radio-cancer therapy specialist Algeta ASA (Oslo) has added Hilde Furberg as Non-executive Director to its board.

The nuclear chemist has 30 years of experience in the pharmaceutical industry. Furberg is currently Senior VP Rare Disease EMEA at Genzyme (now Sanofi). Prior to Genzyme, she spent 15 years at Baxter. She is a Non-executive Director on the Board of Clavis Pharma ASA, and is also a board member at Copenhagen Capacity. Her previous board memberships include Probi AB and Pronova Biopharma ASA (until its acquisition by BASF).

10.05.2013 Claus Schollmeier has left Swiss Santhera AG to follow in the footsteps of Suppremol CEO Peter Buckel, who is resigning.

Schollmeier has led Santhera since its foundation in 2004, and in 2011 became head of the firm's board. Prior to that, the biologist was Managing Director of Healthcare/Biotechnology at investment bank ING BHF.

20.05.2013 Karolinska Development AB has proposed a dealmaker to chair its board. The tech transfer specialist nominated Bo Jesper Hansen to follow Hans Wigzell as Chairman of the Board at its annual meeting in mid-May.

Hansen has many years of experience in international contract negotiation, dealmaking and international marketing, as well as extensive knowledge of legislative conditions, pharmacosurveillance, medical marketing and business development. He is currently Chairman of the Board at SOBI and Executive Chairman of the Board at TopoTarget.

17.05.2013 Scancell Holdings plc has named Peter Allen as its Non-Executive Director.

The therapeutic cancer vaccines developer announced it had hired the current Chairman of Clinigen, Chroma Therapeutics, ProStrakan, and Future in April.  Allen brings the firm a broad spectrum of experience ranging from fundraising to restructuring, IPOs to M&As. During his 12-year tenure at Celltech, he led acquisitions of Chiroscience, Medeva and Oxford Glycosciences.

Vorherige Seite3/8Nächste Seite

Stock list

All quotes

TOP

  • MAGFORCE (D)5.90 EUR9.26%
  • ABCAM (UK)387.00 GBP7.72%
  • NANOBIOTIX (F)17.40 EUR7.27%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • NOVACYT (F)4.40 EUR-8.33%

TOP

  • WILEX (D)3.12 EUR310.5%
  • SANTHERA (CH)69.30 CHF132.6%
  • ADDEX (CH)4.07 CHF89.3%

FLOP

  • MERCK KGAA (D)63.71 EUR-50.0%
  • THROMBOGENICS (B)8.87 EUR-38.3%
  • HYBRIGENICS (F)1.72 EUR-34.1%

TOP

  • SANTHERA (CH)69.30 CHF3365.0%
  • GW PHARMACEUTICALS (UK)438.00 GBP812.5%
  • PAION (D)2.80 EUR311.8%

FLOP

  • CYTOS (CH)0.25 CHF-92.7%
  • EVOCUTIS (UK)0.21 GBP-92.1%
  • THROMBOGENICS (B)8.87 EUR-71.1%

No liability assumed, Date: 22.07.2014


Job Advert

Executive Director of the IMI Joint Undertaking

The Innovative Medicines Initiative Joint Undertaking (IMI JU) is a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA).
The Executive Director will lead and manage the Joint Undertaking and take overall responsibility for its operations ensuring the achievement of the Joint Undertaking's objectives. more...

Current issue

All issues

Product of the week

Products

Events

All Events